Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBM AGILE
NCT03970447Phase 3Recruiting
- Sponsor
- Global Coalition for Adaptive Research
- Start
- Jul 2019
- Primary completion
- Jun 2028
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 3 trial of regorafenib, paxalisib, dianhydrogalactitol, VT1021, troriluzole in glioblastoma (GBM), sponsored by Global Coalition for Adaptive Research. Started Jul 2019; status: recruiting.
02
Drugs
regorafenibpaxalisibdianhydrogalactitolVT1021troriluzole
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03970447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03970447.